The U.S. Food and Drug Administration (FDA) has ordered pharmaceutical companies, specifically Novo Nordisk and Eli Lilly, to remove warnings about potential suicidal thoughts and behaviors from the labels of their obesity medications.

After a review In a thorough review, the FDA concluded that there is no increased risk of suicide associated with GLP-1 drugs for obesity, such as Wegovy and Saxenda. This analysis eliminates uncertainty about the safe use of these drugs by patients. The agency emphasized that GLP-1 receptor agonist drugs approved to treat diabetes have been on the market without similar warnings, underscoring the inconsistency in previous labeling. Reactions and Implications: Physicians have expressed mixed opinions about the FDA's warnings regarding suicide risk in antidepressants, particularly those directed at young people. Recent studies indicate that these “black box warnings” implemented since 2004 have led to a drastic reduction in treatments for pediatric depression, which paradoxically increased rates of suicide attempts and deaths. Experts such as Dr. Stephen Soumerai of Harvard argue that the warnings caused unintended negative effects, such as a 20-45% drop in diagnoses and medical visits for depression, without improvements in surveillance or observable benefits to mental health. Dr. Roger McIntyre of the University of Toronto urges a “recalibration” of these recommendations, as the harms outweigh the benefits in young populations. While Dr. Lisa R. Fortuna of the American Psychiatric Association acknowledges that the FDA's intentions were good in promoting monitoring,However, it emphasizes the need for close follow-up (every two weeks initially) and discussing the risks of untreated depression versus antidepressants with families. No post-advisory studies showed reductions in suicides, leading to a consensus on the lack of effectiveness of this approach.

FDA officials have emphasized that this measure will ensure consistent messaging on the labeling of all approved GLP-1 drugs, benefiting patients and physicians by providing clear and accurate information.

GLP-1 Drugs and Mental Health

There are specific considerations and protocols when prescribing GLP-1 drugs (such as semaglutide or liraglutide) related to mental health, although there are no standardized universal guidelines due to mixed evidence.

Pre-screening. Physicians should screen for a history of depression, anxiety, or suicidal ideation before prescribing, as some studies suggest increased risks, while others do not. It is recommended to avoid them in patients with a serious psychiatric history and to monitor for initial symptoms.

Monitoring during treatment. Active surveillance for changes in mood, anxiety, or suicidal thoughts is advised, informing family members and discontinuing treatment if signs appear. Studies show overall psychiatric safety, but with possible improvements in emotional well-being.

You may also be interested in: